Role of JAK inhibitors in RA and PsA

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on the Role of JAK inhibitors in RA and PsA
(JAK) inhibitors are a class of medications that play a crucial role in managing rheumatoid arthritis (RA). RA is an autoimmune disorder characterized by chronic inflammation of the joints, leading to pain, swelling, and potential joint destruction. JAK inhibitors work by blocking the activity of Janus kinases, enzymes involved in the signaling pathways that trigger inflammation. By inhibiting these pathways, JAK inhibitors reduce the inflammatory response, alleviating symptoms and slowing disease progression. They offer an alternative to traditional disease-modifying antirheumatic drugs (DMARDs) and biologics, providing effective treatment options for patients who do not respond adequately to conventional therapies.
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis, affecting joints and causing pain, stiffness, and swelling. JAK inhibitors are emerging as a valuable treatment option for PsA. Similar to their role in RA, these inhibitors target the Janus kinase pathways that mediate immune responses and inflammation. By disrupting these pathways, JAK inhibitors help reduce joint inflammation, improve physical function, and potentially slow the progression of joint damage.
Therefore, get an overall knowledge of the updated role of JAK inhibitors in RA and PsA
.

See More Webinars @ Hidoc Webinars